PDS Biotech Q2 net loss $11.5M ($0.37/sh); cash $60.6M; Phase 3 protocol submitted to FDA

PDS Biotechnology Corp

2023-Q2 EPS reported -$0.69

Net loss of $11.5M ($0.37 per share) vs. $5.8M ($0.20 per share) in Q2 2022.
R&D expenses rose to $8.0M from $3.8M; G&A rose to $4.7M from $3.3M.
Cash and equivalents $60.6M; management says sufficient for 12 months.
Submitted final Phase 3 VERSATILE-003 protocol to FDA to start Q4 2023.
VERSATILE-002 interim data showed 12-month OS rate of 87% with favorable safety.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PDS Biotechnology Corp reported for the three and six months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute, EPS ($0.37) per basic share and diluted share.

Period: for the three and six months ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute
EPS: ($0.37) per basic share and diluted share
Result: reported results

Exact text from the filing

Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and diluted share

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-23-039661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.